Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model

BackgroundIrinotecan is a topoisomerase I inhibitor that is commonly used as a chemotherapeutic regimen for the treatment of metastatic colorectal cancer (CRC) by producing cytotoxic DNA damage. However, drug resistance frequently occurs, underscoring the importance of developing newer treatment str...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Robert W. Lentz, Adrian T. A. Dominguez, Nicole Baranda Balmaceda, John J. Arcaroli, Stacey M. Bagby, Cameron A. Binns, Stephen G. Smoots, Marilyn M. Jackson, Morgan Macbeth, Tessa Holmstoen, Tapahsama Banerjee, Phaedra A. Whitty, S. Stephen Yi, Christopher H. Lieu, Wells A. Messersmith, Todd M. Pitts
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2026-03-01
Schriftenreihe:	Frontiers in Oncology
Schlagworte:	chemotherapy colorectal cancer eltanexor selinexor XPO1
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1721685/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!